Harvard Bioscience, Inc. (NASDAQ:HBIO) Director Buys $22,926.92 in Stock
Harvard Bioscience, Inc. (NASDAQ:HBIO) Director Bertrand Loy acquired 7,372 shares of Harvard Bioscience stock in a transaction dated Friday, September 13th. The shares were bought at an average cost of $3.11 per share, with a total value of $22,926.92. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
Bertrand Loy also recently made the following trade(s):
- On Wednesday, September 11th, Bertrand Loy acquired 15,590 shares of Harvard Bioscience stock. The shares were bought at an average cost of $3.01 per share, with a total value of $46,925.90.
NASDAQ HBIO traded up $0.05 during mid-day trading on Friday, hitting $3.16. The company’s stock had a trading volume of 122,700 shares, compared to its average volume of 299,201. The company’s 50 day simple moving average is $2.51 and its 200 day simple moving average is $2.89. Harvard Bioscience, Inc. has a twelve month low of $1.51 and a twelve month high of $5.75. The company has a current ratio of 2.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $116.43 million, a price-to-earnings ratio of 21.07 and a beta of 1.53.
A number of hedge funds and other institutional investors have recently bought and sold shares of HBIO. Tower Research Capital LLC TRC grew its position in Harvard Bioscience by 401.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,752 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 11,011 shares during the period. BNP Paribas Arbitrage SA grew its position in Harvard Bioscience by 635.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,567 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 6,538 shares during the period. Susquehanna International Group LLP acquired a new stake in Harvard Bioscience in the 2nd quarter valued at $34,000. Jefferies Group LLC acquired a new stake in Harvard Bioscience in the 2nd quarter valued at $36,000. Finally, Citadel Advisors LLC acquired a new stake in Harvard Bioscience in the 2nd quarter valued at $118,000. 65.39% of the stock is owned by institutional investors and hedge funds.
HBIO has been the subject of several recent analyst reports. ValuEngine raised shares of Harvard Bioscience from a “sell” rating to a “hold” rating in a research report on Wednesday. Janney Montgomery Scott downgraded shares of Harvard Bioscience from a “buy” rating to a “neutral” rating and set a $2.00 price objective for the company. in a research report on Monday, July 8th. Zacks Investment Research downgraded shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Finally, Benchmark reaffirmed a “buy” rating on shares of Harvard Bioscience in a research report on Friday, July 19th.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.
Read More: Cash Asset Ratio
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.